ArticleDiabetologia2021
Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk.
Article in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00179777 (TRIGR - Trial to Reduce IDDM in the Genetically at Risk), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TRIGR - Trial to Reduce IDDM in the Genetically at Risk
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Joint modelling on clinical trials in clinical journals: a systematic review.BMC medical research methodology · 2026Pooled it
- High BMI and the risk for incident type 1 Diabetes Mellitus: a systematic review and meta-analysis of aggregated cohort studies.Cardiovascular diabetology · 2023Pooled it
- BMI Normalization Is Associated With Lower Risk of Progression to Type 1 Diabetes, Primarily in Youth.Diabetes care · 2026Article
- Impact of Body Size on Preclinical Type 1 Diabetes Development and Progression.Diabetes care · 2026Review
- Effect of Body Weight on Glycaemic Indices in People with Type 1 Diabetes Using Continuous Glucose Monitoring.Journal of clinical medicine · 2024Article
- Cumulative incidence of type 1 diabetes in two cohorts of children with different national gluten recommendations in infancy.Acta diabetologica · 2024Article
- An unwelcome inheritance: childhood obesity after diabetes in pregnancy.Diabetologia · 2023Review
- Physical Activity and the Development of Islet Autoimmunity and Type 1 Diabetes in 5- to 15-Year-Old Children Followed in the TEDDY Study.Diabetes care · 2023Article
- Can type 1 diabetes be an unexpected complication of obesity?Frontiers in endocrinology · 2023Review
- Dietary Intake and Body Mass Index Influence the Risk of Islet Autoimmunity in Genetically At-Risk Children: A Mediation Analysis Using the TEDDY Cohort.Pediatric diabetes · 2023Article
- Review
- Identification of novel differentially expressed genes in type 1 diabetes mellitus complications using transcriptomic profiling of UAE patients: a multicenter study.Scientific reports · 2022Article
- Growth in Children with HLA-Conferred Susceptibility to Type 1 Diabetes.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- Autoimmune reaction against pancreatic beta cells in children and adolescents with simple obesity.Frontiers in endocrinology · 2022Observational
- The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children.International journal of molecular sciences · 2021Review
- Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality.Frontiers in immunology · 2021Review
- Neoepitopes in Type 1 Diabetes: Etiological Insights, Biomarkers and Therapeutic Targets.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 12 institutions in 7 countries.
Funding
Abstract
aims/hypothesisWe aimed to evaluate the relationship between childhood growth measures and risk of developing islet autoimmunity (IA) and type 1 diabetes in children with an affected first-degree relative and increased HLA-conferred risk. We hypothesised that being overweight or obese during childhood is associated with a greater risk of IA and type 1 diabetes.
methodsParticipants in a randomised infant feeding trial (N = 2149) were measured at 12 month intervals for weight and length/height and followed for IA (at least one positive out of insulin autoantibodies, islet antigen-2 autoantibody, GAD autoantibody and zinc transporter 8 autoantibody) and development of type 1 diabetes from birth to 10-14 years. In this secondary analysis, Cox proportional hazard regression models were adjusted for birthweight and length z score, sex, HLA risk, maternal type 1 diabetes, mode of delivery and breastfeeding duration, and stratified by residence region (Australia, Canada, Northern Europe, Southern Europe, Central Europe and the USA). Longitudinal exposures were studied both by time-varying Cox proportional hazard regression and by joint modelling. Multiple testing was considered using family-wise error rate at 0.05.
resultsIn the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) population, 305 (14.2%) developed IA and 172 (8%) developed type 1 diabetes. The proportions of children overweight (including obese) and obese only were 28% and 9% at 10 years, respectively. Annual growth measures were not associated with IA, but being overweight at 2-10 years of life was associated with a twofold increase in the development of type 1 diabetes (HR 2.39; 95% CI 1.46, 3.92; p < 0.001 in time-varying Cox regression), and similarly with joint modelling. CONCLUSIONS/
interpretationIn children at genetic risk of type 1 diabetes, being overweight at 2-10 years of age is associated with increased risk of progression from multiple IA to type 1 diabetes and with development of type 1 diabetes, but not with development of IA. Future studies should assess the impact of weight management strategies on these outcomes.
trial registrationClinicalTrials.gov NCT00179777.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.